Stock Analysis

Hancom Lifecare Third Quarter 2024 Earnings: ₩2.00 loss per share (vs ₩2.00 loss in 3Q 2023)

KOSE:A372910
Source: Shutterstock

Hancom Lifecare (KRX:372910) Third Quarter 2024 Results

Key Financial Results

  • Revenue: ₩23.6b (up 14% from 3Q 2023).
  • Net loss: ₩46.0m (loss narrowed by 32% from 3Q 2023).
  • ₩2.00 loss per share (in line with 3Q 2023).
earnings-and-revenue-growth
KOSE:A372910 Earnings and Revenue Growth November 11th 2024

All figures shown in the chart above are for the trailing 12 month (TTM) period

Hancom Lifecare Earnings Insights

Looking ahead, revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 9.3% growth forecast for the Commercial Services industry in South Korea.

Performance of the South Korean Commercial Services industry.

The company's shares are down 3.7% from a week ago.

Risk Analysis

You still need to take note of risks, for example - Hancom Lifecare has 2 warning signs we think you should be aware of.

Valuation is complex, but we're here to simplify it.

Discover if Hancom Lifecare might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.